NASDAQ:SLGC Standard BioTools (SLGC) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free SLGC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.93▼$2.3150-Day Range$2.10▼$2.8352-Week Range$1.73▼$3.79Volume33.91 million shsAverage Volume10.83 million shsMarket Capitalization$394.95 millionP/E RatioN/ADividend YieldN/APrice Target$2.43 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Get Standard BioTools alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Standard BioTools Stock (NASDAQ:SLGC)SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him SLGC Stock News HeadlinesApril 18, 2024 | morningstar.comStandard BioTools Inc LABFebruary 25, 2024 | finance.yahoo.comLAB May 2024 2.500 callApril 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…January 5, 2024 | finanznachrichten.deStandard BioTools Inc.: Standard BioTools Stockholders Approve Merger with SomaLogicJanuary 4, 2024 | finance.yahoo.comMadryn Asset Management Demands SomaLogic’s Board Address Repeated, Unprecedented Adjournments of Tainted Special MeetingJanuary 4, 2024 | finance.yahoo.comMadryn Asset Management Addresses SomaLogic’s Apparent Failure to Obtain Requisite Shareholder Support for the Proposed Merger with Standard BioToolsJanuary 3, 2024 | finance.yahoo.comProxy Advisory Firm Egan-Jones Recommends SomaLogic Shareholders Vote Against Proposed Merger with Standard BioToolsJanuary 2, 2024 | finance.yahoo.comSomaLogic Urges Stockholders to Maximize Value of Their Investment by Voting "FOR" Pending Merger with Standard BioToolsApril 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…January 1, 2024 | markets.businessinsider.comBoston Millennia Partners To Vote Against Proposed Merger Of SomaLogic With Standard BioToolsDecember 29, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firms Glass Lewis and ISS Both Recommend SomaLogic Stockholders Vote "FOR" Proposed Merger with Standard BioToolsDecember 29, 2023 | finance.yahoo.comMadryn Asset Management Highlights Increasing Public Shareholder Opposition to Value-Destructive SomaLogic Merger and Calls on Company to Make Additional DisclosuresDecember 29, 2023 | finance.yahoo.comSomaLogic Board Reiterates Value-Maximizing Transaction with Standard BioTools is in Best Interests of All StockholdersDecember 28, 2023 | msn.comSomaLogic founder, CTO urge shareholders to vote against mergerDecember 28, 2023 | finance.yahoo.comDr. Larry Gold and Dr. Jason Cleveland Issue Open Letter to SomaLogic Stockholders Opposing SomaLogic's Proposed Merger with Standard BioToolsDecember 26, 2023 | finance.yahoo.comSomaLogic Issues Statement Correcting Madryn Asset Management's Misleading DisclosureDecember 26, 2023 | finance.yahoo.comMadryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of AlternativesDecember 24, 2023 | businesswire.comMadryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw “Cautionary Support” for SomaLogic’s Value-Destructive Proposed Merger with Standard BioToolsDecember 24, 2023 | finance.yahoo.comMadryn Asset Management Sends Letter to ISS Respectfully Requesting it Withdraw "Cautionary Support" for SomaLogic’s Value-Destructive Proposed Merger with Standard BioToolsDecember 22, 2023 | finance.yahoo.comTikvah Management Announces Intention to Vote against Somalogic’s Proposed Merger with Standard BioToolsDecember 22, 2023 | finance.yahoo.comMadryn Asset Management Reiterates Alternative Path to SomaLogic’s Value-Destructive Proposed Merger with Standard BioToolsDecember 22, 2023 | finance.yahoo.comMadryn Asset Management Highlights Newly-Disclosed Conflicts of Interest Related to Proposed SomaLogic Merger with Standard BioToolsDecember 21, 2023 | finance.yahoo.comMadryn Asset Management Issues Letter to Shareholders Correcting False and Misleading Statements in SomaLogic’s Recent Investor PresentationDecember 21, 2023 | finance.yahoo.comSomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioToolsDecember 18, 2023 | businesswire.comMadryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard ...December 18, 2023 | finance.yahoo.comMadryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote "AGAINST" the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioToolsNovember 22, 2023 | morningstar.comSomaLogic Inc Class ASee More Headlines Receive SLGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:SLGC CUSIPN/A CIK1837412 Webii.cmlifesciencesspac.com Phone303-625-9000FaxN/AEmployees451Year FoundedN/APrice Target and Rating Average Stock Price Target$2.43 High Stock Price Target$2.50 Low Stock Price Target$2.30 Potential Upside/Downside+15.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-109,160,000.00 Net Margins-159.54% Pretax Margin-159.08% Return on Equity-24.72% Return on Assets-21.62% Debt Debt-to-Equity RatioN/A Current Ratio17.79 Quick Ratio17.29 Sales & Book Value Annual Sales$97.67 million Price / Sales4.04 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.70Miscellaneous Outstanding Shares188,070,000Free Float160,049,000Market Cap$394.95 million OptionableOptionable Beta1.64 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Stephen A. Williams BS (Age 64)MB, Ph.D., Chief Medical Officer Comp: $648.03kMr. Adam Taich (Age 49)Interim CEO Mr. Pi Zheng (Age 51)Interim Chief Accounting Officer Dr. Jason Cleveland Ph.D.Chief Technology OfficerDr. Nebojsa Janjic Ph.D. (Age 63)Chief Science Officer Mr. Ruben Gutierrez J.D. (Age 49)General Counsel Ms. Alison Marie Roelke (Age 49)Chief People Officer Dr. Shane Bowen Ph.D.Chief Research & Development OfficerMore ExecutivesKey CompetitorsNational ResearchNASDAQ:NRCATRenewNYSE:RERENexxen InternationalNASDAQ:NEXNGannettNYSE:GCITTECNASDAQ:TTECView All CompetitorsInsidersAdam TaichSold 21,584 sharesTotal: $50,290.72 ($2.33/share)Ruben GutierrezSold 9,211 sharesTotal: $21,461.63 ($2.33/share)Alison Marie RoelkeSold 3,434 sharesTotal: $8,001.22 ($2.33/share)View All Insider Transactions SLGC Stock Analysis - Frequently Asked Questions Should I buy or sell Standard BioTools stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares. View SLGC analyst ratings or view top-rated stocks. What is Standard BioTools' stock price target for 2024? 3 analysts have issued 1 year price objectives for Standard BioTools' stock. Their SLGC share price targets range from $2.30 to $2.50. On average, they predict the company's share price to reach $2.43 in the next year. This suggests a possible upside of 15.9% from the stock's current price. View analysts price targets for SLGC or view top-rated stocks among Wall Street analysts. This page (NASDAQ:SLGC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Standard BioTools Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
